Analytical Data
-
基因名
SLFN11
- Application
-
别名
SLFN11; Schlafen family member 11; EC 3.6.-.-
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q7Z7L1
-
表达区间
345-901aa
-
分子量
69.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLFN11 (Sleepy Family Member 11) is a member of the Schlafen gene family known for its roles in cellular stress response and regulation of cell proliferation. Recent studies have highlighted its potential as a tumor suppressor, particularly in the context of various cancers, including breast and ovarian cancers, where its expression correlates with improved patient outcomes. The significance of SLFN11 in DNA repair mechanisms has garnered attention, as it interacts with key proteins involved in the DNA damage response, such as RAD51. Recombination deficiencies, frequently observed in tumors, may be counteracted by SLFN11, providing a potential therapeutic target. Research into SLFN11 recombinant proteins aims to elucidate its structural and functional properties, helping to understand its mechanisms of action at the molecular level. This knowledge could pave the way for novel treatments that exploit SLFN11’s role in enhancing DNA repair processes in chemotherapy-resistant tumors. As researchers develop recombinant forms of SLFN11, they hope to facilitate high-throughput screens for small molecules that can modulate its activity, opening new avenues for cancer therapy and improving patient management in oncological settings.
